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The effects of iron dextran on the oxidative stress in cardiovas-
cular tissues of rats with chronic renal failure.
Background. Redox-active iron can promote oxidative stress
and tissue injury by catalyzing hydroxyl radical generation and
lipid peroxidation. Intravenous iron preparations are routinely
administered in conjunction with erythropoietin to treat anemia
in patients with chronic renal failure (CRF), a condition that is
marked by oxidative stress and inflammation. This treatment
frequently elevates iron burden, which can potentially intensify
oxidative stress and, thus, cardiovascular disease in this popu-
lation.
Methods. We studied renal function and oxidative stress pa-
rameters in the cardiovascular tissues of CRF (5/6 nephrec-
tomized) and sham-operated control rats 3 months after a single
intravenous infusion of iron dextran (500 mg/kg).
Results. Arterial pressure was equally elevated and creati-
nine clearance was equally reduced in both iron-treated and
-untreated CRF groups. Iron administration significantly raised
the blood hemoglobin, serum iron concentration, and transfer-
rin saturation in both CRF and control groups. Iron administra-
tion resulted in a significant rise in plasma concentration of lipid
peroxidation product, malondialdehyde in the CRF rats, and
an insignificant rise in the control group. Plasma oxidized low-
density lipoprotein (LDL) concentration was increased in the
CRF groups, and was not affected by iron administrations. Iron
administration raised nitrotyrosine abundance in the aorta of
CRF but not in the control group. Left ventricular tissue abun-
dance of p22phox subunit of NAD(P)H oxidase was elevated
in CRF group and was not affected, whereas p67phox subunit
abundance was raised by prior iron administration. Iron ad-
ministration insignificantly lowered aorta p22phox, but had no
effect on p67phox subunit abundance in the treated CRF group.
Previous iron administration significantly lowered superoxide
dismutase and catalase abundance in the aorta and glutathione
peroxidase in the left ventricle of CRF animals, but did not sig-
nificantly change these parameters in the iron-treated control
animals.
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Conclusion. A single intravenous injection of iron dextran
increased oxidative stress in the cardiovascular tissues in the
CRF group, but not the control rats, pointing to heightened
susceptibility to iron-mediated toxicity in CRF. However, ad-
ministration of iron dextran did not adversely affect kidney
function, and favorably affected hemoglobin concentration in
rats with CRF induced by renal mass reduction. Further studies
are needed to explore the effects of other parenteral iron prepa-
rations, repeated intravenous iron administration, and presence
of comorbid conditions such as diabetes.
Anemia is a common and disabling feature of chronic
renal failure (CRF). Different parenteral iron (Fe) prepa-
rations are usually used in conjunction with erythro-
poietin to treat anemia in CRF patients [1]. Unlike
tightly regulated absorption of oral Fe supplements, in-
travenously administered Fe precludes the body’s ability
to prevent iron overload [2]. Moreover, intravenous (IV)
administration of Fe preparations results in a rapid and
nonphysiologic rise in Fe load for processing in short pe-
riods. It should be noted that because of their particular
chemical structures, which minimize release of catalyt-
ically active Fe in extracellular space, the risk of acute
toxicity with the commercially available parenteral Fe
preparations is negligible. However, a low-level, clinically
insidious toxicity may occur with each IV injection of
these preparations [3, 4]. Moreover, routine administra-
tion of IV Fe on a regular basis without close monitoring
of Fe stores can result in Fe overload in some patients
[5]. As a major transition metal, Fe catalyzes lipid perox-
idation and hydroxyl radical production, and as such, can
promote oxidative stress, cytotoxicity, and tissue injury [3,
4, 6]. This has raised a justifiable concern that prescrip-
tion of IV Fe preparations on the regular basis, without
vigilant monitoring of Fe stores and utilization, may exac-
erbate oxidative stress and, hence, cardiovascular disease
[7–11] and inflammation, which are well known conse-
quences of CRF [12, 13].
The iron hypothesis proposes that excess iron is as-
sociated with increased risk for cardiovascular disease.
While some studies have found an association between
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high iron levels or increased iron consumption with ele-
vated risk for cardiovascular disease in subjects with or
without renal disease [14–17], others have not found such
an association [18, 19]. In addition, iron overload has been
implicated in the pathogenesis of renal disease [20–23].
The underlying mechanisms of association between
iron overload and the cardiovascular disease and re-
nal injury have not been fully elucidated. Iron overload
has been shown to result in glomerulosclerosis, tubular
atrophy, interstitial fibrosis, and iron deposition in the
glomeruli, proximal and distal tubules [20–23]. These re-
nal lesions are associated with and perhaps caused by
increased reactive oxygen species (ROS) and diminished
nitric oxide (NO) availability [23, 24]. The generation of
highly reactive cytotoxic hydroxyl radicals (·HO) is facil-
itated by iron, which catalyzes the interaction of super-
oxide (O2−) and hydrogen peroxide (H2O2) by Fenton
or Haber-Weiss reactions [25]. In addition, iron catalyzes
the peroxidation of unsaturated lipids, and generation of
lipoperoxides that are capable of promoting atheroscle-
rosis and renal damage [24, 26, 27]. Moreover, iron over-
load may increase the risk of cardiovascular disease by
promoting infection and inflammation [8], and limiting
NO activity in the atherosclerotic vessels [28].
Oxidative stress can be caused by increased ROS gen-
eration, antioxidant depletion, or both. Nicotinamide
adenine dinucleotide (phosphate) [NAD(P)H] oxidase
has emerged as the main source of ROS in the renal
and cardiovascular system. In the present study, we in-
vestigated the long-term effect of a single IV injection
of high-dose iron dextran on markers of oxidative stress,
NAD(P)H oxidase, and antioxidant enzymes in the car-
diovascular tissues of the CRF and sham-operated con-
trol rats.
METHODS
Animals
Male Sprague Dawley rats weighing 220 to 250 g (Har-
lan Sprague Dawley, Inc., Indianapolis, IN, USA) were
housed in a climate-controlled space with 12-hour day
and night cycles, and were provided free access to reg-
ular rat chow and water. The animals were randomly
assigned to the normal control group (CTL, N = 6),
Fe-loaded control group (CTL + Fe, N = 6), CRF group
(N = 6), and Fe-loaded CRF group (CRF + Fe, N = 6).
The CRF groups underwent 5/6 nephrectomy by surgical
resection of the upper and lower thirds of the left kidney,
followed by right nephrectomy four days later. The con-
trol groups underwent sham operation. The procedures
were carried out under general anesthesia (sodium pento-
barbital, 50 mg/kg intraperitoneally) using strict hemosta-
sis and aseptic techniques. The nephrectomy procedures
were accomplished via dorsal incisions as described in our
earlier study [29]. Animals placed in the Fe-loaded group
received a single IV injection of an iron dextran complex
(Sigma Chemical Co., St. Louis, MO, USA) at a dose
of 500 mg elemental iron/kg body weight. Animals were
observed for 13 weeks, at which point tail arterial pres-
sure was measured by tail plethysmography (Harvard
Apparatus, Natick, MA, USA) as described previously
[30], and timed urine collections were obtained using
metabolic cages. The animals were then anesthetized by
intraperitoneal injection of pentobarbital (50 mg/kg) and
euthanized by exsanguination by cardiac puncture. Tho-
racic aorta and heart were immediately excised, cleaned
with phosphate-buffered saline, frozen in liquid nitrogen,
and stored at −70◦C. Plasma was separated and stored at
−70◦C until being processed. The procedures were car-
ried out between the hours of 9 a.m. to 11 a.m. The exper-
imental protocol employed in this study was approved by
the Institutional Animal Care and Use Committee of the
University of California, Irvine.
Measurement of plasma malondialdehyde (MDA) and
oxidized low-density lipoprotein (LDL) concentration
Plasma MDA concentration was measured by high-
pressure liquid chromatography as described in our ear-
lier study [31]. Plasma oxidized LDL (oxLDL) was
measured by enzyme-linked immunosorbent assay
(ELISA) using a kit purchased from ALPCO Diagnostics
(Windham, NH, USA).
Tissue preparation
Homogenates (25% wt/vol) of heart (left ventri-
cle) and thoracic aorta were prepared in 10 mmol/L
HEPES buffer, pH 7.4, containing 1 mmol/L ethylenedi-
aminetetraacetic acid, 1 mmol/L dithiothreitol, 10 lg/mL
leupeptin, 2 lg/mL aprotinin, and 1 mmol/L phenyl-
methylsulfonyl fluoride at 0◦C to 4◦C with a polytron ho-
mogenizer. Homogenates were centrifuged at 9000g for
10 minutes at 4◦C to remove nuclear fragments and tissue
debris without precipitating membrane fragments. The
supernatant was used for determination of tissue nitroty-
rosine abundance, and the protein expression of super-
oxide dismutase (SOD) isoforms (Cu Zn SOD and Mn
SOD), catalase (CAT), glutathione peroxidase (GPX),
and NAD(P)H oxidase (p22phox and p67phox subunit). To-
tal protein concentration was determined by means of a
BCA kit purchased from Bio-Rad, Inc. (Hercules, CA,
USA).
Measurements of SOD, CAT, GPX, and NAD(P)H
oxidase subunits
Total cellular protein (20 lg) was electrophoresed in
4% to 20% Tris-glycine sodium dodecyl sulfate polyacry-
lamide gels (Invitrogen, Carlsbad, CA, USA) at 150 V
for 120 minutes. Proteins were transferred onto nitro-
cellulose membranes (Millipore Corp., Bedford, MA,
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Table 1. Body weight, systolic blood pressure, serum creatinine, creatinine clearance, serum iron, TIBC, transferrin saturation, and hemoglobin
concentration in normal control group (CTL), Fe-loaded control group (CTL + Fe), CRF group, and Fe-loaded CRF group (CRF + Fe)
CTL CTL + Fe CRF CRF + Fe
Body weight g
Week 0 292 ± 3 292 ± 3 276 ± 8 287 ± 5
Week 13 462 ± 12 428 ± 5 410 ± 10a 401 ± 6a
Systolic blood pressure mm Hg 111 ± 1 118 ± 2 143 ± 4a,c 144 ± 2a,c
Serum creatinine mg/dL 0.27 ± 0.02 0.31 ± 0.02 1.25 ± 0.13d 0.96 ± 0.05d
Creatinine clearance mL/min 4.56 ± 0.62 4.16 ± 0.26 1.09 ± 0.16a,b 1.24 ± 0.13a,b
Creatinine clearance mL/min/kg 9.82 ± 1.23 9.75 ± 0.68 2.65 ± 0.37a,b 3.07 ± 0.28a,b
Serum iron lmol/L 42.6 ± 3.2 68.9 ± 6.4a,c 37.3 ± 2.2 67.4 ± 3.6a,c
Serum TIBC lmol/L 100.0 ± 3.3 114.5 ± 6.3 81.3 ± 2.2d 116.1 ± 4.6
Transferrin saturation % 42.3 ± 2.0 59.7 ± 2.5a,c 45.8 ± 2.1 58.1 ± 1.8a,c
Hemoglobin g/dL 13.8 ± 0.3 15.4 ± 0.4d 12.7 ± 0.4 13.9 ± 0.6c
TIBC, total iron binding capacity. Data are presented as mean ± SEM.
aP < 0.05 vs. CTL group.
bP < 0.05 vs. CTL + Fe group.
cP < 0.05 vs. CRF group.
dP < 0.05 vs. all other groups.
USA), blocked in 5% dry milk in T-TBS (0.02 mol/L
Tris/0.15 mol/L NaCl, pH 7.5 containing 0.1% Tween 20)
at room temperature for three hours, washed three times
with T-TBS, and incubated with the primary antibodies
(GPX, 1:250; SOD, 1:1000; CAT, p22phox, and p67phox,
1:2000) for three hours at room temperature. All an-
tibodies were purchased from Calbiochem (San Diego,
CA, USA), except antibodies to p22phox and p67phox,
which were purchased from BD Transduction Labora-
tories (Lexington, KY, USA). After washing five times
with T-TBS, the blots were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies (an-
tisheep for SOD and GPX, 1:2000; antirabbit for CAT
and p22phox, 1:2000; antimouse for p67 phox, 1:2000) at
room temperature for two hours. After washing five times
with T-TBS, each membrane was developed with en-
hanced chemiluminescence reagent (Perkin Elmer Life
Sciences, Inc., Boston, MA, USA) and subjected to au-
toluminography for one to 15 minutes. The autolumino-
graphs were scanned with a laser densitometer (Model
PD 1211; Molecular Dynamics, Sunnyvale, CA, USA) to
determine the relative optical densities of the bands. In
all instances, the membranes were stained with Ponceau
stain to verify the uniformity of protein load and transfer
efficiency across the test samples. Membranes failing the
test were discarded and measurements were repeated.
Measurements of tissue nitrotyrosine
Tissue nitrotyrosine abundance was determined by
Western blot analysis as described in our earlier stud-
ies [32]. The primary anti-nitrotyrosine antibody (Up-
state Biotechnology, Inc., Lake Placid, NY, USA) and
the HRP-conjugated antimouse secondary antibody were
used at 1:1000 dilutions.
Data analysis
Data are presented as mean ± SEM. Analysis of vari-
ance (ANOVA) with post hoc multiple comparison tests
were used in statistical analysis of the data. P values less
than 0.05 were considered significant.
RESULTS
General data
Data are summarized in Table 1. Body weight at the
beginning of the study was comparable between groups.
However, body weights obtained at the end of the ob-
servation period were significantly lower in the CRF and
CRF + Fe groups compared with the treated and un-
treated CTL groups. The CRF and CRF + Fe groups ex-
hibited a marked increase in systolic blood pressure and a
significant reduction in creatinine clearance. As expected,
both serum iron concentration and transferrin saturation
were significantly higher in Fe-injected groups (CTL + Fe
and CRF + Fe group) than those in the untreated groups.
The hemoglobin (Hb) concentration in CTL + Fe group
(15.4 ± 0.4 g/dL) was significantly higher than those found
in the other groups. The Hb concentration in the CRF +
Fe group was higher than that of untreated CRF group
(13.9 ± 0.6 g/dL vs. 12.7 ± 0.4 g/dL, P = 0.047).
Markers of oxidative stress
The CRF + Fe group showed the highest plasma MDA
concentration as compared with the other groups. The
plasma oxLDL content was higher in CRF and CRF +
Fe groups as compared with CTL and CTL + Fe groups.
The aortic tissue nitrotyrosine (footprint of NO inactiva-
tion by ROS) content in CRF + Fe group was higher than
those found in the other groups. Interestingly, iron admin-
istration did not significantly alter the measured oxida-
tive stress markers in the sham-operated controls. These
findings point to the increased ROS-mediated oxidation
of lipid and nitric oxide in iron injected CRF animals,
but not sham-operated control rats. Data are shown in
Figures 1 through 3.
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Fig. 1. Plasma malondialdehyde (MDA) levels at the end of 13-week
observation period in control rats (CTL), Fe-injected control rats (CTL
+ Fe), chronic renal failure rats (CRF), and Fe-injected CRF rats (CRF
+ Fe). (N = 6 in each group) ∗P < 0.05 vs. CTL group.
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Fig. 2. Plasma oxidized low-density lipoprotein (oxLDL) levels in con-
trol rats (CTL), Fe-injected control rats (CTL + Fe), chronic renal fail-
ure rats (CRF), and Fe-injected CRF rats (CRF + Fe). (N = 6 in each
group) ∗P < 0.05 vs. CTL and CTL + Fe group.
Tissue NAD(P)H oxidase subunits
The protein abundance of the p22phox subunit was sig-
nificantly increased in the left ventricle of CRF and CRF
+ Fe groups compared with those found in the CTL
and CTL + Fe groups. Although mean value for p22phox
abundance in CRF + Fe group was higher than that
in CRF group, the difference did not reach statistical
significance. The p67phox protein abundance was signif-
icantly increased in the left ventricle of CRF + Fe an-
imals compared with those found in other groups. The
p22phox and p67phox subunits were increased in the aorta
of the untreated CRF group. Iron administration insignif-
icantly lowered aorta p22phox, but had no effect on p67phox
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Fig. 3. Representative Western blots and corresponding group data
illustrating nitrotyrosine abundance of thoracic aorta in control rats
(CTL, N = 5), Fe-injected control rats (CTL+Fe, N = 5), chronic renal
failure rats (CRF, N = 6), and Fe-injected CRF rats (CRF + Fe, N =
6). ∗P < 0.05 vs. CTL + Fe group.
abundance in the treated CRF group. Data are shown in
Figure 4.
Tissue SOD, CAT, and GPX
The CRF + Fe group exhibited a significant reduction
in the aortic tissue Mn SOD protein as compared with that
in the CRF group. Similarly, the CRF + Fe group exhib-
ited a significant reduction in aortic tissue CAT protein
abundance and a significant reduction in left ventricular
tissue GPX protein. However, prior iron administration
did not significantly change these parameters in the iron-
treated control rats. Data are illustrated in Figure 5.
DISCUSSION
As expected, the untreated CRF animals exhibited a
significant reduction in blood hemoglobin concentration.
Administration of a single dose of iron dextran resulted
in significant amelioration of anemia in the CRF animals.
Similarly, iron administration led to a significant rise in
Hb concentration in the sham-operated controls. Thus,
iron dextran, per se (without exogenous erythropoietin
administration), stimulated erythropoiesis in both CRF
and control rats. In confirmation of the earlier studies
[9, 33], the CRF animals employed in the present study
exhibited significant elevation of plasma MDA and ox-
idized LDL levels. These findings point to the presence
of oxidative stress, which is a well-known feature of CRF
[9–11, 34, 35]. Oxidative stress plays an important role
in the pathogenesis of atherosclerotic cardiovascular dis-
ease [33, 36–38]. Premature atherosclerotic cardiovascu-
lar disease is the main cause of death in patients with
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Fig. 4. Representative Western blots and corresponding group data illustrating p22phox and p67phox subunit of NAD(P)H oxidase abundance of
left ventricle (A, B) and aorta (C, D) in control rats (CTL, N = 5), Fe-injected control rats (CTL + Fe, N = 5), chronic renal failure rats (CRF,
N = 6), and Fe-injected CRF rats (CRF + Fe, N = 6). ∗P < 0.05 vs. CTL and CTL + Fe group; †P < 0.05 vs. all other groups; ‡P < 0.05 vs. CTL
group.
chronic renal failure [13, 39, 40]. Given the frequent use of
IV iron in CRF patients and the well-known pro-oxidant
property of catalytically active iron, we sought to exam-
ine the effects of iron loading on the ROS-generating
and antioxidant systems in the heart and aorta of CRF
and control rats.
NAD(P)H oxidase and its tissue-specific isoforms have
emerged as the main source of superoxide production
in the cardiovascular tissues, and their activation/up-
regulation has been implicated in the pathogenesis of
atherosclerotic plaque formation [38, 41–43]. NAD(P)H
oxidase consists of two membrane-associated (gp91phox
and p22phox) and two cytoplasmic (p47phox and p67phox)
subunits. The enzyme catalyzes the one-electron reduc-
tion of molecular oxygen, using NAD(P)H as an elec-
tron donor. The ROS generated in the body are normally
contained by a highly complex antioxidant defense sys-
tem that consists of numerous enzymes, as well as many
endogenous and dietary antioxidant compounds. Super-
oxide dismutase, catalase, and glutathione peroxidase are
among the most important antioxidant enzymes [44]. An
imbalance between ROS generation and antioxidant ca-
pacity favoring the former leads to oxidative stress.
The untreated CRF animals employed in this study ex-
hibited a significant up-reguation of p22phox in the heart
and aorta, and a significant up-regulation of p67phox in
the aorta. The up-regulation of the NAD(P)H oxidase
subunits in the cardiovascular tissues found here and in
the remnant kidney and liver shown in our earlier study
[11] point to a systemic increase in superoxide producing
capacity in CRF animals. Iron loading with a single IV
dose of iron dextran led to a more than two-fold rise in
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Fig. 5. Representative Western blots and corresponding group data
illustrating (A) Mn SOD, (B) CAT, and (C) GPX protein abundance of
aorta and left ventricle in control rats (CTL, N = 5), Fe-injected control
rats (CTL + Fe, N = 5), chronic renal failure rats (CRF, N = 6), and
Fe-injected CRF rats (CRF + Fe, N = 6). ∗P < 0.05 vs. all other groups;
†P < 0.05 vs. CRF group.
p67phox abundance in the left ventricle of the CRF ani-
mals, but had no discernible effect on either heart p22phox
or aorta p67phox. Thus, iron dextran administration had
limited impact on NAD(P)H oxidase expression in the
heart, but not in the aorta of CRF animals, and no signif-
icant impact in the normal animals.
Despite oxidative stress, which should have caused a
compensatory up-regulation of antioxidant enzymes, Mn
SOD, catalase, and GPX were unchanged in the aorta
and heart of the untreated CRF animals, representing a
maladaptive response. Iron loading with a single dose of
iron dextran led to a further decline in expression of these
enzymes in the cardiovascular tissues. This was accompa-
nied by a further rise in the plasma lipid peroxidation
product, malondialdehyde. Thus, iron loading appears to
adversely affect antioxidant enzyme expression in car-
diovascular tissues of CRF animals. However, an identi-
cal dose of iron dextran had no effect on the expression
of these antioxidant enzymes in the cardiovascular tis-
sues of the control animals. This observation points to
greater sensitivity of CRF animals to the pro-oxidant ac-
tion of excess iron stores compared with the normal con-
trol animals. It should be noted that pro-oxidant action of
catalytically active iron is primarily related to its ability
to promote lipid peroxidation, and to catalyze genera-
tion of highly cytotoxic hydroxyl radicals from hydrogen
peroxide via Fenton or Haber-Weiss reactions [25, 45].
The iron-induced down-regulations of catalase and glu-
tathione peroxidase, which catalyze the reduction of
hydrogen peroxide and lipoperoxides, can potentially
compound the toxicity of iron in CRF animals. It is of
note that the available parenteral iron preparations are
designed to minimize the release in the catalytically active
free iron in the circulation [46, 47]. Similarly, binding of
iron by transferrin in the circulation, and by ferritin within
the cells, ensures safe transport and storage of this vitally
essential, yet highly toxic, element. However, the capac-
ity of these biologically protective mechanisms is lim-
ited and can fail when iron burden is too high. Likewise,
significant reductions in pH, and lysis of these proteins
by proteolytic enzymes, can lead to release of free iron
from the binding proteins. Release of lysosomal enzymes
and hydrogen ions into the microenvironment surround-
ing the inflammatory cells creates the above-mentioned
condition. In the recent years, compelling evidence has
emerged identifying CRF as an inflammatory state [12,
13]. This phenomenon may explain the observed exac-
erbation of oxidative stress in CRF animals, but not the
control rats given identical amounts of IV iron dextran in
a single dose 3 months before the final study.
The authors wish to point out that the dose of iron used
in the present study was far greater than that used in the
clinical practice. The reason for choosing such a high dose
is that rats are highly resistant to the toxic effects of iron.
In fact, rats treated with more than twice the amount
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used here (1.2 g/kg) showed only a mild sign of toxicity
in a 10-month observation period [22]. This is evidenced
by the lack of significant impact of the given amount in
our control rats. Therefore, caution should be exercised
in comparing the amount of iron used in rats with those
used in humans.
Despite evidence of moderate increase in oxidative
stress, one-time administration of IV iron dextran did
not adversely affect the renal function, and favorably af-
fected blood hemoglobin concentration in CRF rats with
renal mass reduction, but no other underlying disease or
comorbid conditions. Further studies are needed to the
discern effects of other commonly prescribed parenteral
iron preparations, as well as repetitive dosing to simulate
clinical practice. In addition, it is necessary to explore the
impact of comorbid conditions such as diabetes.
CONCLUSION
A single IV injection of iron dextran increased oxida-
tive stress in the cardiovascular tissues in the CRF but not
the control rats, pointing to heightened susceptibility to
iron-mediated toxicity in CRF. However, administration
of iron dextran did not adversely affect kidney function,
and favorably affected hemoglobin concentration in rats
with CRF induced by renal mass reduction without co-
morbid conditions. Further studies are needed to explore
the effects of other parenteral iron preparations, repeated
intravenous iron administration, and presence of comor-
bid conditions such as diabetes.
Reprint requests to Nosratola D. Vaziri, M.D., MACP, Division of
Nephrology and Hypertension, UCI Medical Center, 101 The City Drive,
Bldg. 53, Room 125, Route 81, Orange, CA 92868.
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